Financials in USD. Standardized financial statements.
A compact view of how 60 Degrees Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue? | $1.01M | $607,574 | $253,573 | $223,208 | $1.16M | $2.18M |
| Revenue Growth? | +65.5% | +139.6% | +13.6% | -80.8% | -46.8% | 0.0% |
| Cost of Revenue? | $781,695 | $384,765 | $474,550 | $432,370 | $850,742 | $702,989 |
| Gross Profit? | $223,776 | $222,809 | -$220,977 | -$209,162 | $309,598 | $1.48M |
| Gross Margin? | +22.3% | +36.7% | -87.1% | -93.7% | +26.7% | +67.8% |
| Operating Expenses? | $7.98M | $9.94M | $4.93M | $1.54M | $1.43M | $1.90M |
| Operating Income? | -$7.76M | -$9.71M | -$5.15M | -$1.75M | -$1.12M | -$418,130 |
| EBITDA? | -$7.28M | -$7.88M | -$1.43M | -$2.11M | -$1.01M | -$341,170 |
| Income Before Tax | -$7.37M | -$7.96M | -$3.81M | -$6.18M | -$4.26M | -$3.05M |
| Income Tax Expense | $0 | $250 | $250 | $500 | $1,000 | $1,000 |
| Net Income? | -$7.37M | -$7.95M | -$3.77M | -$6.18M | -$4.25M | -$3.03M |
| EPS? | $-11.73 | $-74.20 | $-3.80 | $-4.28 | $-2.96 | $-2.08 |
| Diluted EPS? | $-11.73 | $-74.20 | $-3.80 | $-4.28 | $-2.96 | $-2.08 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality